UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                             ----------------------

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                              --------------------

         Date of report (Date of earliest event reported): June 15, 2006

                            Applied DNA Sciences, Inc
               (Exact Name of Registrant as Specified in Charter)


           Nevada                   002-90539                  59-2262718
      (State or Other        (Commission File Number)        (IRS Employer
       Jurisdiction                                       Identification No.)
     of Incorporation)


                       25 Health Sciences Drive, Suite 113
                           Stony Brook, New York 11790
               (Address of Principal Executive Offices) (Zip Code)

                                  631-444-6861
              (Registrant's telephone number, including area code)

                                 Not Applicable
          (Former Name or Former Address, if Changed Since Last Report)


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2 below):

|_|   Written communications pursuant to Rule 425 under the Securities Act
      (17 CFR 230.425)

|_|   Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))






Item 1.01 Entry into a Material Definitive Agreement.
Item 2.03 Creation of a Direct Financial Obligation.
Item 3.02 Unregistered Sales of Equity Securities.

      On June 15, 2006, Applied DNA Sciences, Inc., a Nevada corporation (the
"Company"), completed the second tranche of a private placement (the
"Placement") of up to 140 units at $50,000 per unit for sale to "accredited
investors" who are not a "U.S. person," as each is defined in regulations
promulgated under the Securities Act. In the first tranche, completed on May 2,
2006, the Company sold 20 units for aggregate gross proceeds of $1,000,000. In
this second tranche, the Company sold 59 units for aggregate gross proceeds of
$2,950,000. Each such unit consists of (i) a $50,000 Principal Amount 10%
Secured Convertible Promissory Note and (ii) a warrant to purchase 100,000
shares of the Company's common stock exercisable for a period of four years
commencing on May 2, 2007, at a price of $0.50 per share. Each such warrant may
be redeemed at the option of the Company at a redemption price of $0.001 upon
the earlier of (i) June 15, 2009, and (ii) the date a registration statement for
the resale of the underlying common stock has been declared effective by the
Securities and Exchange Commission (the "Commission"), and the Company's stock
has traded on The Over the Counter Bulletin Board at or above $1.00 per share
for 20 consecutive trading days. The principal and accrued but unpaid interest
under the promissory notes are convertible into shares of common stock of the
Company at a price of $0.50 per share by the holder of the promissory notes at
any time from June 15, 2006, through June 15, 2007, and shall automatically
convert on June 15, 2007 at a 20% discount to the average of the closing bid
prices of the Company's common stock on trading days during the 12 months prior
to such conversion. The promissory notes bear interest at the rate of 10% per
annum and are due and payable in full on August 2, 2007. Any principal and
accrued but unpaid interest under the promissory notes not paid when due,
whether upon maturity, acceleration or otherwise, shall bear interest at the
lesser of 12% or the maximum rate permissible by law. At any time prior to
conversion, the Company will have the right to prepay the promissory notes and
accrued but unpaid interest thereon upon 3 days notice, allowing the holders to
convert the promissory notes during such notice period.

      Until the principal and accrued but unpaid interest under the promissory
notes is paid in full, or converted into common stock of the Company, the
promissory notes will be secured by a security interest in all of the assets of
the Company. This security interest will be pari passu with the security
interest granted to the holders of $1,500,000 of $50,000 principal amount 10%
secured convertible promissory notes issued as part of a private placement of
the Company completed on March 8, 2006. The Company may issue up to $4,500,000
of debt in addition to the remaining $3,050,000 that may be sold in the
Placement that may be secured by a security interest in all of the Company's
assets, which interest would be pari passu to the security interest granted to
the holders of the promissory notes issued in March.

      In connection with the Placement, each purchaser of a unit has entered
into a subscription agreement and a registration rights agreement with the
Company. Pursuant to this registration right agreement, the Company will prepare
and file a registration statement with the Commission for the resale of the
common stock underlying the promissory notes and the warrants within 30 days of
the Company's registration statement on Form SB-2, as amended (SEC File No.
333-122848), being declared effective by the Commission, and to use the
Company's reasonable best efforts to have the registration statement for the
resale of the common stock underlying the promissory notes and the warrants
declared effective by the Commission by no later than 180 days after filing. The
obligations of the Company to file and have such registration statement declared
effective shall terminate as to any holder of the units upon the earlier of the
date: (a) when all of such holder's common stock underlying the promissory notes
and the warrants may be sold during a single three (3) month period under Rule
144 of the Securities Act; and (b) when all of such holder's common stock
underlying the promissory notes and the warrants may be transferred under Rule
144(k) of the Securities Act, unless such holder later becomes an affiliate of
the Company (as defined in Rule 144 of the Securities Act) in which case the
Company's obligation shall be revived until such holder's rights otherwise
terminate under clause (a) above.



      Arjent Limited served as the Company's placement agent in the Placement.
The Company has agreed to pay to Arjent Limited from the gross proceeds of the
second tranche of the Placement: (a) a commission equal to 10% of the gross
proceeds of the second tranche Placement; and (b) a non-accountable expense
allowance equal to 3% and non-accountable due diligence expenses equal to 2%, of
the gross proceeds of the second tranche of the Placement.

      The Company claims an exemption from the registration requirements of the
Securities Act for the private placement of the units pursuant to Regulation S
promulgated under the Securities Act because each of the units were sold in an
"offshore transaction" to persons who are not a "U.S. person," in each case as
defined in Regulation S.


Item 9.01 Financial Statements and Exhibits

      (d)   Exhibits.

      Exhibit     10.1 Form of Subscription Agreement by and between Applied DNA
                  Sciences, Inc. and each purchaser of a unit, filed as an
                  exhibit to the current report on Form 8-K filed with the
                  Commission on May 4, 2005 and incorporated herein by
                  reference.

      Exhibit     10.2 Form of 10% Secured Convertible Promissory Note of
                  Applied DNA Sciences, Inc., filed as an exhibit to the current
                  report on Form 8-K filed with the Commission on May 4, 2005
                  and incorporated herein by reference.

      Exhibit     10.3 Form of Warrant Agreement of Applied DNA Sciences, Inc.,
                  filed as an exhibit to the current report on Form 8-K filed
                  with the Commission on May 4, 2005 and incorporated herein by
                  reference, filed as an exhibit to the current report on Form
                  8-K filed with the Commission on May 4, 2005 and incorporated
                  herein by reference.

      Exhibit     10.4 Form of Registration Rights Agreement by and between the
                  Applied DNA Sciences, Inc. and each purchaser of a unit, filed
                  as an exhibit to the current report on Form 8-K filed with the
                  Commission on May 4, 2005 and incorporated herein by
                  reference.






                                    SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                       Applied DNA Sciences, Inc.
                                       (Registrant)



                                       By: /s/ James  Hayward
                                       --------------------------------------
                                       James Hayward
                                       Chief Executive Officer




Date: June 15, 2006